Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869796 | 0.85 | NOS2 (0.38) | ALDH1A1SMN1; SMN2KMT2AKDM4EMEN1 | |
| SCHEMBL4865356 | 0.79 | HTR2A (0.42) | HPGDMAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4874428 | 0.76 | MAPT (0.43) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL4872690 | 0.76 | MAPT (0.43) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL5635326 | 0.72 | HPGD (0.35) | HPGDMAPTALDH1A1POLBKMT2A | |
| SCHEMBL4868760 | 0.71 | SMN1; SMN2 (0.42) | HPGDMAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5634829 | 0.69 | HPGD (0.35) | HPGDMAPTALDH1A1KMT2A | |
| SCHEMBL4670055 | 0.67 | SMN1; SMN2 (0.59) | MAPTALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL6251696 | 0.66 | ALDH1A1 (0.54) | HPGDMAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1164238 | 0.66 | NOS2 (0.57) | MAPTALDH1A1LMNASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7408067-B2 | Aza-cyclic compounds as modulators of acetylcholine receptors | MERCK + CO., INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20050070520-A1 | Aza-cyclic compounds as modulators of acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| EP-1467986-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062224-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070520-A1 | Aza-cyclic compounds as modulators of acetylcholine receptors | CHRNG, CHRNA4, CHRNB4 | HPGD 1819/4885MAPT 3850/4885ALDH1A1 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.